Editor’s choice: recent research highlights from the International Journal of Nanomedicine
Farooq A Shiekh,1 Abdul-Rahman M Abu-Izzah,2 Vivian J Lee,2 Syed Mudassar1
1Department of Clinical Biochemistry, Sher-I-Kashmir Institute of Medical Sciences (SKIMS), Srinagar, India; 2Department of Basic Medical Sciences, Avalon University School of Medicine, Curacao, the Netherlands
Is nanomedicine really less harmful?
Evaluation of: Thakkar A, Chenreddy S, Thio A, Khamas W, Wang J, Prabhu S. Preclinical systemic toxicity evaluation of chitosan-solid lipid nanoparticle-encapsulated aspirin and curcumin in combination with free sulforaphane in BALB/c mice. Int J Nanomedicine. 2016;11:3265–3276.
Nanomedicine1 has increasingly received a tremendous attention over the past two decades as a potential multidimensional field, developing nano-applications that are transforming a host of medical products and services,2,3 including drug delivery4 and health-monitoring devices, and the possibility of gaining new insights about “undruggable targets” and treatment through atomic-scale precision is increasing rapidly.5 Although it is uncertain as to which of the new delivery platforms will become the most effective and useful, it is certain that many new approaches will be investigated in the years to come.4,6
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]